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Abstract
Herein we hypothesise the positive effects of kojibiose (KJ), a prebiotic disaccharide, selected for reducing hepatic expression of inﬂammatory
markers in vivo that could modulate the severity of saturated arachidic acid (ARa)-induced liver dysfunction in hyperglycaemic rats. Animals
were fed daily (20 d) with ARa (0·3mg) together or not with KJ (22 mg approximately 0·5 %, w/w diet). Glucose, total TAG and cholesterol
contents and the phospholipid proﬁle were determined in serum samples. Liver sections were collected for the expression (mRNA) of
enzymes and innate biomarkers, and intrahepatic macrophage and T-cell populations were analysed by ﬂow cytometry. ARa administration
increased the proportion of liver to body weight that was associated with an increased (by 11 %) intrahepatic macrophage population. These
effects were ameliorated when feeding with KJ, which also normalised the plasmatic levels of TAG and N-acyl-phosphatidylethenolamine in
response to tissue damage. These results indicate that daily supplementation of KJ signiﬁcantly improves the severity of ARa-induced hepatic
alterations.
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Prebiotics are dietary substances (mostly consisting of oligo-
saccharides and NSP, poorly digested by human enzymes)
that are prone to be fermented by beneﬁcial gut microbiota
involving concomitant health implications. Kojibiose (KJ, 2-O-α-
D-glucopyranosyl-α-D-glucopyranose) is a naturally occurring
carbohydrate that can be found in a variety of foodstuffs and
beverages, such as sake and koji extracts, beer, honey or starch
hydrolysate. However, KJ is naturally present at low levels,
making its isolation from natural sources difﬁcult at high
scale and demanding an efﬁcient biotechnological synthesis
process(1). Interestingly, KJ has been reported to be an
excellent candidate as a prebiotic ingredient according to its
in vitro selectivity of microbial fermentation using individual
bacteria from Biﬁdobacterium, Streptococcus, Lactobacillus or
Eubacterium genera(2,3), as well as with cultures of mixed
human faecal bacteria(4).
The European Food Safety Authority has recently approved a
health claim linking non-digestible carbohydrates (i.e. fructo-
oligosaccharides (FOS)) and a reduction of postprandial gly-
caemic (and insulinaemic) responses(5). Notwithstanding,
opposite results have been obtained from type 2 diabetic (T2D)
patients about the regulatory effect of prebiotic on glucose
homoeostasis(6). Besides, the reported prebiotic-mediated
effects on circulating blood levels in hyperlipidaemic human
subjects appear variable(7).
Prior research has largely focused on total energy intake and
consumption, with a continuous positive balance promoting
diseases such as obesity, fatty liver and ﬁnally nonalcoholic fatty
liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) and/or
the metabolic syndrome. NAFLD incurs a high risk for the develop-
ment of T2D and other major features of the metabolic syndrome;
thus, plasma glucose and TAG, among others, constitute risk
factors of NAFLD. Recent data suggest that the composition of the
food, irrespective of energy count, and its inﬂuence on and
interaction with the gut microbiota, and ﬁnally their crosstalk
with the host’s intestinal immune system, may be even more
important determinants of intestinal and liver-related disorders(7,8).
Experimental data and incipient human studies indicate the
positive effects of prebiotics in improving the regulation of glucose
homoeostasis, in addition to inﬂuencing the immune function both
directly through their interaction with innate mediators and/or by
modifying the gut microbiota composition(9,10).
The liver acts as a central organ for the turnover and trans-
formation of nutrients and metabolites that pass through it from
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the intestine. In addition, the intestine also supplies regulatory
signals of inﬂammatory processes that stem from the intestinal
mucosa and immune system, highlighting the importance of the
so-called gut–liver axis in the development of metabolic and
liver-related diseases. Experimental data from murine models
support the potential beneﬁcial inﬂuence of prebiotics on liver
function, contributing to normalising the hepatic PPAR-γ mRNA
expression and the production of proinﬂammatory hepcidin
peptide(11). Fermentation of prebiotics was also positively
associated with decreased glucose-induced TNF-α and IL-6
levels in human subjects(12). Furthermore, prebiotic structures
can potentially interact with innate mediators through the
toll-like receptor (TLR)-4/NF-κB signalling pathway(13,14), thus
promoting positive effects such as reducing TAG accumulation
and the endogenous synthesis of cholesterol, favouring liver
physiology(7,15). Alterations in the phospholipid (PL) proﬁle
have also been reported in diabetic patients(16), pointing to
these as new players with a key role in metabolic diseases, but
there is no evidence of the inﬂuence of prebiotic feeding on
either humans or animal models.
Several attempts have been made to develop animal models
approaching major pathophysiological manifestations of
diet-induced metabolic disorders such as obesity and insulin
resistance(17). Overall, there is still an open debate about the
deﬁnition of a low- (<10 % of energy) or high-fat (>30–50 % of
energy) diet, and a wide variety of diets are used in animal
studies. Rodents are less sensitive to the development of
metabolic disorders, thus requiring greater fat intake than do
humans to induce metabolic abnormalities. Additionally, there
is a lack of data on how and which prebiotics could modulate
metabolic derangement and ﬁnally liver dysfunction. In this
context, treatment of animals with a low dose of streptozotocin
(STZ) resulted in hyperglycaemia in animals without requiring
exogenous insulin administration(18,19). Thus, this model toge-
ther with the concurrent administration of SFA approaches early
stages of fat-induced liver alterations that ultimately could
promote liver diseases. Undoubtedly, further reﬁnement of the
available animal models is desirable, but it is considered
appropriate to explore initial pathogenic mechanisms and
potential pharmaceutical or nutritional interventions at early
stages of liver dysfunction.
KJ has demonstrated advantageous features ameliorating
inﬂammation-mediated perturbations in the liver in comparison
with 4-galactosyl-kojibiose (O-β-D-galactopyranosyl-(1,4)-O-
(α-D-glucopyranosyl-(1,2))-α-D-glucopyranose) and galacto-
oligosaccharides derived from lactulose(20). Thus, the objective
of this work was to study the inﬂuence of KJ-based feeding on
arachidic acid (ARa)-induced liver injury in a hyperglycaemic
model of young rats.
Methods
Synthesis and puriﬁcation of kojibiose
KJ (65 % purity on DM) was obtained from the hydrolytic action
of a Kluyveromyces lactis β-galactosidase on 4′-galactosyl-
kojibiose and puriﬁed by using a Saccharomyces cerevisiae
yeast treatment as has previously been shown. The second
most important compound was leucrose (19 %) followed by 8 %
of yeast metabolites produced during yeast fermentation
(mainly minor amounts of polyalcohols and/or organic acids).
Microbiological assays demonstrated that the microbial load
(yeast and moulds, total and sporulated aerobic bacteria,
enterobacteria) was, in all cases, lower than 3× 101 colony
forming unit/g(1).
Animals
For the studies, female Wistar albino rats, aged 3 weeks with an
average weight of 61·4 (SD 5·6) g, were obtained from the
University of Valencia Animal Service. Animal experiments
were carried out in strict accordance with the recommendations
in the Guide for the Care and Use of Laboratory Animals of
University of Valencia (SCSIE, University of Valencia, Spain)
and the protocol (2013/007/UVEG005 type 2) was approved by
its Ethics Committee.
Experimental design
Animals were randomly distributed into four different groups
(n 7/group): (1) controls received a standard AIN-93G diet, and
three groups were treated with a low dose of STZ (two doses of
25 mg/kg per d with a time lapse of 24 h)(17) and subjected to
different treatments; (2 fed the standard diet; (3 administered
ARa (20 : 0) – 0·3mg daily for 20 d; (4) administered ARa –
0·3mg daily for 20 d together with KJ (0·5 %, w/w daily
consumption of diet) during the period of treatment(21). The rats
were maintained in an environment of controlled temperature
(21–23ºC), humidity (55 %) and 12h light–12h dark cycle, with
food and mineral-free water provided ad libitum. Weight gain
and food intake were measured every 2 d and monitored
throughout the experiment. Food uptake per body weight and
weight gain per food uptake were determined in each group.
After treatment, rats were anaesthetised (isoﬂuran) and killed by
exsanguination (heart puncture).
Blood collection and morphometric evaluation of the liver
Whole blood samples were preserved in EDTA-treated tubes to
prevent coagulation (at room temperature) for haematological
analyses. Total concentration (mmol/l) of glucose (Química
Analítica Aplicada SA), TAG and cholesterol (Química Analítica
Aplicada SA) was quantiﬁed using commercial kits commonly
used for clinical diagnosis. Analytical interferences were dis-
carded by conﬁrmation of the standard compound provided in
the commercial kit.
Complete livers were extracted, rinsed with Krebs’ buffer and
weighed. Thereafter, sections (approximately 100 mg) of the
liver were immersed in RNAlater buffer (Qiagen) and snap-
frozen in liquid N2 for gene expression analyses. Samples from
central lobules (0·51 (SD 0·04) g) were immersed in a trypsin
solution for 30 min before homogenisation and immune
cell analysis by ﬂow cytometry (Coulter). The following
ﬂuorochrome-conjugated antibodies were used: anti-rat CD45,
CD4, CD8 and Cd11b/c (eBioscience); ﬂuorescence was
analysed by ﬂow cytometry (EPICS XL-MCL). Samples were
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prepared with the Immunoprep kit (Beckman Coulter)
according to the manufacturer’s instructions and further
analysed on an FACSCanto System (BD Biosciences).
Real-time RT-quantitative PCR
Total RNA was extracted from liver tissue samples using an
RNeasy mini kit (Qiagen) following the protocol provided by
the manufacturer. One microgram of total RNA was converted
to double-stranded complementary DNA (cDNA) using AMV RT
(Promega). PCR was performed with primers designed for the
following Rattus norvegicus genes: angiopoietin-like protein 4
(ANGP4) (forward 5′-CTT TTT ACG CTG CTG CCG TT-3′,
reverse 5′-AAC CCA AGA CCT TGA CCG TG-3′); TLR4 (forward
5´-TTC TCA CGG CCT CCG CTG GT-3', reverse 5'-AAG GGA
GGC TAA CCG GAA AGG GA-3'); LDL receptor (LDLr) (forward
5′-GGA CCC GTG ATC CTG TGT TT-3′, reverse 5′-AAA GAA
AAC CAC TCG GGG CT-3′); PPARγ (forward 5'-TGA TCC TAC
GGC CAG ACA GA-3′, reverse 5′-GGG AGG TTG TCC CTG
GAA TG-3′) and β-actin (forward 5′-CTC TTC CAG CCT TCC
TTC CT-3′, reverse 5′-TAG AGC CAC CAA TCC ACA CA-3′);
the latter was used as a housekeeping gene. Samples of each
animal tissue were measured in duplicate, and gene expression
was expressed as fold-change. The PCR mix (25 μl reaction
volume) in triplicate consisted of 7·5 μl SYBR Green I Master
mix (Roche), 1·25 μmol/l primers and 2·5 μl cDNA. PCR reac-
tions were performed in a LightCycler® 480 (Roche) system
under the following conditions: one cycle at 95ºC for 5 min, and
forty cycles at 60ºC for 20 s and at 72ºC for 45 s. Data were
analysed using the 2ΔCt method, being normalised against
β-actin and expressed as fold-change.
Serum arachidic acid quantiﬁcation and phospholipids proﬁle
Blood samples (0·3 ml) were centrifuged (3000 g for 10 min at
4ºC) (Jouan) and the supernatant mixed with 700 µl formic acid
(0·1 %, v/v) in acetonitrile. The mixtures were loaded onto
HybridSPE®-PL cartridges (Cat No. 55269-U; Supelco) to purify
the PL fraction(22).
The analysis was performed on an Agilent 1260 HPLC system
(Agilent) connected on line to a QqTOF MS (5600 TripleTOF;
AB Sciex) equipped with an electrospray interface. The column
used in these analyses was a C18 1·7 µm particle, 2·1× 50 mm
(Waters). The mobile phases consisted of deionised water, 18
MΩcm (A) and acetonitrile (B), both containing 0·1 % (v/v)
formic acid. Aliquots (5 µl) of the PL puriﬁed fractions were
injected in each cycle and the analysis was performed with
the following gradient (0·8ml/min): 20 % B for 2 min to 100 % B
in 16 min, held at 100 % for 7 min. Two independent samples
from each animal were analysed. The QqTOF MS instrument
was operated under the following conditions: nebulisation and
solvation pressure, 50 psi; curtain gas pressure, 30 psi; temperature,
450ºC; ion-spray voltage ﬂoating, 3500 V; de-clustering potential,
110 V; and energy collision, 60 V. Serum ARa concentrations
were quantiﬁed using appropriate standard curves. Areas
corresponding to the total ion current were used to compare the
PL proﬁle.
Analysis of SCFA and lactic acid
Aliquots (0·17 (SD 0·04) g) of colon samples were kept in 0·2 ml
of 2 N-H2SO4. The samples were homogenised (1 min) using a
TissueRuptor (Qiagen) and vortexed for 30 s. Afterwards, the
mixtures were centrifuged (10 000 g, 10 min) and the super-
natant was collected and diluted in deionised water prior to
ﬁltration (0·45 µm, MillexGN; Millipore).
The quantiﬁcation of organic acids was carried out on a 1200
Agilent HPLC system equipped with a multisolvent pump and a
multivariable wavelength absorbance detector set at 214 nm
(1200 Series; Agilent Technologies). The separation was per-
formed on a BioBasis C18 column (250× 4·6mm) (Thermo).
The elution was performed using 1 % acetronitrile in 20 mM-
phosphate buffer adjusted to pH 2·20 with phosphoric acid (A)
and water–acetronitrile (80:20, v/v, B) according to the fol-
lowing gradient: 0 min, 0 % B; 5 min, 0 % B; 12 min, 10 % B;
19 min, 10 % B.
Statistical analysis
Statistical analyses were performed using SPSS version15 soft-
ware (SPSS Inc.). Differences between the different groups of
treatments were established with the Student’s t test. One-way
ANOVA was used to compare the inﬂuence of feeding KJ to the
different treated groups of animals. Individual means were
tested using pairwise comparison with Tukey’s multiple com-
parison tests when effects were signiﬁcant. Statistical sig-
niﬁcance was established at P< 0·05 for all comparisons.
Results
Changes in body and liver weight
There were no signiﬁcant differences in daily food (energy)
intake between the different groups of treatment (71·5 kJ/d
(17·1 kcal/d), 17·7 % protein, 60·1 % carbohydrate, 7·2 % fat)
over the study period. The lower body weight of animals
administered ARa/KJ (approximately 20 %) in relation to those
administered only ARa (Fig. 1(A)) suggests that energy intake is
not the only determinant in the development of the disease.
Morphometric comparison of the proportion of liver to body
weight revealed signiﬁcant (P< 0·05) increases in the liver
weight of all hyperglycaemic animals relative to untreated
controls (Fig. 1(B)). Notably, animals administered ARa/KJ
showed signiﬁcantly lower (P= 0·01) proportions of liver to
body weight than did animals fed ARa alone.
Biochemical parameters
Serum concentrations of biochemical parameters of metabolic
relevance are shown in Table 1. Animals treated with STZ
showed a 2-fold increase in serum glucose and TAG and a
4-fold increase in cholesterol concentration relative to the
untreated controls. The administration of ARa alone or together
with KJ affected the mean serum glucose concentrations
aggravating hyperglycaemia. The administration of ARa was
signiﬁcantly associated with a 2·5-fold increase in TAG levels
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compared with animals treated with STZ, but not total cholesterol.
In addition, the concurrent administration of ARa together with
KJ is associated with decreased serum TAG concentration in
relation to animals administered ARa alone.
Expression of hepatic biomarkers
Changes in hepatic expression levels of biomarkers of lipid
metabolism and innate immune mediators are shown in Fig. 2.
Treatment of animals with STZ increased mRNA transcripts of
all targeted genes compared with controls. Additionally, animals
fed ARa showed signiﬁcantly increased expression levels of
both ANGP4 and LDLr, reﬂecting the physiological response to
inhibit fat uptake and favour the reverse transport of cholesterol
to the liver. KJ did not exert any additional effect when it was
fed to animals administered ARa. However, animals fed ARa
together with KJ showed signiﬁcantly increased expression
values of PPARα in comparison with those fed only ARa, sug-
gesting an increased fatty acid metabolism. Animals adminis-
tered ARa showed higher transcripts of TLR4, and those values
were not affected by the administration of KJ.
Intrahepatic lymphocyte and macrophage population
The leucocyte population was identiﬁed with the marker CD45,
and further phenotyping analyses of lymphocyte subsets
(CD4+, CD8+) and macrophage (CD11b/c+) populations were
conducted on this population (Fig. 3). Treating animals with
STZ only signiﬁcantly increased the numbers of inﬁltrated CD4+
cells. Administration of ARa did not cause further signiﬁcant
increases in either the CD4+ or the CD8+ population, although
intrahepatic CD11b/c+ cells increased by 31·5 %. Feeding KJ to
animals administered ARa had positive effects in reducing
CD11b/c+ cells to counts similar to those found in STZ-treated
animals.
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Fig. 1. Changes in body weight (A) and the relative liver to body weight (B) in
untreated controls and hyperglycaemic animals administered saturated
arachidic acid (ARa) alone or together with kojibiose (ARa/KJ). Values are
means (n 7), and standard deviations represented by vertical bars. a,b,cMean
values with unlike letters were significantly different (P< 0·05) between the
different groups of treatment. * Mean value was significantly different from of
the control group (P< 0·05), STZ. streptozotocin.
Table 1. Total glucose (GLUC), TAG and cholesterol (CHOL) concentrations (mmol/l) in untreated controls and hyperglycaemic animals administered
saturated arachidic acid (ARa) alone or together with kojibiose (ARa/KJ)
(Mean values and standard deviations; n 7)
GLUC (mmol/l) TAG (mmol/l) CHOL (mmol/l) ARa (mmol/l)
Treatment Mean SD Mean SD Mean SD Mean SD
Control 121·2a 23·3 89·9a 7·4 100·3a 18·2 8·1a 0·2
STZ 213·5a,b 70·7 224·5b 32·4 430·0b 22·8 10·7b 1·2
ARa 316·2b,c 74·1 561·8c 43·7 454·2b 70·6 13·9c 0·6
ARa/KJ 372·1c 39·5 264·7b 19·8 417·8b 45·1 9·7a,b 1·0
STZ, streptozotocin.
a,b,c Mean values within a row with unlike superscript letters were significantly different (P<0·05) for each parameter between the different groups of treatment.
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Fig. 2. Hepatic expression of hepatic biomarkers in untreated controls (CON)
and hyperglycaemic animals administered saturated arachidic acid (ARa)
alone or together with kojibiose (ARa/KJ). Values are means (n 7), and
standard deviations represented by vertical bars. , PPARα; , angiopoietin-
like protein 4 (ANGP4); , LDL receptor (LDLr); , toll-like receptor 4 (TLR4);
STZ, streptozotocin.
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Phospholipid proﬁle
All PL identiﬁed in aliquots of plasma were identiﬁed using
high-resolution MS after liquid chromatography (LC-QqTOF
MS). The groups of animals treated with STZ that were not fed
either with ARa or KJ showed higher lysophosphatidylcholine
(LPC) and non-altered concentration of phosphatidylserine
(PS), whereas plasma levels of all other identiﬁed PL were
decreased in comparison with control animals (Fig. 4). In
animals fed ARa, decreased levels of PS were detected, whereas
all other identiﬁed PL were increased. Feeding KJ to animals
decreased the concentrations of lysophosphatidylethanolamine
(LPE), N-acyl-phosphatidylethenolamine (NAPE) and phos-
phatidylinositol diphosphate (PIP2), approximating these
values to those quantiﬁed for animals treated with STZ, but not
fed ARa. Additionally, the group of animals administered ARa
together with KJ showed reduced LPC and PS values than did
animals fed only ARa.
Quantiﬁcation of SCFA and lactic acid
The concentrations of organic acids quantiﬁed in colon contents
of animals from the different groups of treatment are shown in
Table 2. Signiﬁcantly lower concentrations of formic acid were
detected in all STZ-treated animals compared with control
animals, and were slightly increased by the administration of
ARa and not modiﬁed despite the sequential administration of
KJ. Administration of STZ to animals caused signiﬁcant increa-
ses in acetic and D/L-lactic acid concentrations, which increased
even more in ARa-fed animals. Feeding KJ to animals only
reduced the concentration of D/L-lactic acid signiﬁcantly. An
opposite pattern was observed for propionic acid that appeared
at lowest concentration in ARa-fed animals and normalised to
the values found in the STZ group by the administration of KJ.
i-Butyric acid concentrations only signiﬁcantly increased in the
ARa group.
Discussion
This study reports ﬁndings to expand the positive effects
of feeding prebiotics, particularly the inﬂuence of KJ on the
saturated ARa-induced alterations in an experimental hyper-
glycaemic animal model. ARa was chosen because of its central
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Fig. 3. Phenotyping of intrahepatic lymphocytes (CD4+ and CD8+) and
macrophage (CD11b/c+) population in untreated controls (CON) and
hyperglycaemic animals administered saturated arachidic acid (ARa) alone
or together with kojibiose (ARa/KJ). Values are means (n 7), and standard
deviations represented by vertical bars. a,x,b,yMean values with unlike letters
were significantly different (P< 0·05) for each population between the different
groups of treatment. , CD4+; , CD8+, , CD11b/c+.
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Fig. 4. Plasmatic phospholipid profile in untreated controls and hyperglycaemic
animals administered saturated arachidic acid (ARa) alone or together with
kojibiose (ARa/KJ). Values are means (n 7), and standard deviations represented
by vertical bars. a,b,c,dMean values with unlike letters were significantly different
(P<0·05) for each compound between the different groups of treatment. TIC, total
ion current; PG, phosphatidylglycerol; LPC, lysophosphatidylcholine (20:2); LPE,
lysophosphatidylethanolamine (18:1); PS, phosphatidylserine; NAPE, N-acyl-
phosphatidylethenolamine (20:2); PIP2, phosphatidylinositol diphosphate.
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Table 2. SCFA and lactic acid production in colon contents (µg/g) of untreated controls and hyperglycaemic animals administered saturated arachidic acid
(ARa) alone or together with kojibiose (ARa/KJ)
(Mean values and standard deviations; n 7)
Control STZ ARa ARa/KJ
Organic acids Mean SD Mean SD Mean SD Mean SD
Formic 9·93a 1·15 3·06b 0·31 5·23c 1·33 5·47c 1·19
Acetic 1·63a 0·19 2·79b 0·28 4·60c 1·36 3·58b,c 1·20
Propionic 0·63a 0·07 0·29b 0·10 0·14c 0·02 0·39b 0·04
D/L-Lactic 0·24a 0·03 1·36b 0·18 9·09c 1·61 1·36b 0·18
i-Butyric 0·28a 0·03 0·29a 0·05 0·81b 0·26 0·33a 0·19
STZ, streptozotocin.
a,b,c Mean values within a row with unlike superscript letters were significantly different (P<0·05) for each parameter between the different groups of treatment.
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role in inﬂammation related to injury and many diseased states
and as a lipid second messenger involved in the regulation of
signalling enzymes, such as phospholipase C (PLC)-γ, PLC-δ, and
protein kinase C-α, -β, and -γ isoforms(23). On the basis of the
identiﬁcation of beneﬁcial prebiotics, even without a difﬁcult-to-
achieve massive energy reduction, a better understanding and
the use of beneﬁcial prebiotics can greatly impact the risk of
developing liver-related disorders. As shown, consumption of KJ
signiﬁcantly decreased the plasmatic levels of ARa, and probably
a lower production of hepatotoxic products, which in turn leads
to a low-grade inﬂammation state and liver dysfunction. Feeding
KJ increased the numbers of Biﬁdobacterium spp. (by 12%),
Bacteroides spp. (by 2%) and Enterobacteriaceae (by 4%)
relative to control animals (data not shown).
The animal model used in the present study approaches early
metabolic alterations that, in patients, ultimately can lead to
liver dysfunction and steatosis with inﬂammation. Notably,
there is a quantiﬁed increase in macrophage population in the
liver as well as plasma levels of NAPE, an important inter-
mediary in the biosynthesis of endocannabioid (eCB) agonists
such as anandamide(24). These results are concordant with
previous data in which the increased anandamide concentra-
tions were associated with hepatic lipogenesis in high-fat-fed
mice(25). Taking these data together, a role for the eCB system
in the development of obesity could be suggested, at least in
rodents, probably with an immunomodulatory role in the
activation of inﬂammasome in macrophages(26). The increased
T-cell CD4+ population quantiﬁed in animals fed ARa is
concordant with the CD28-dependent signalling initiated by the
conversion of PIP2 into phosphatidylinositol (3,4,5)-trispho-
sphate (PIP3)(27) that can explain the increased PIP2
concentration quantiﬁed (Fig. 4). However, this study shows
that the period of treatment is not enough to reproduce the
T-cell recruitment involved, effector CD8+ T-cells that are
associated with late steatosis with inﬂammation (NASH)(28).
From these data, one can derive an important role for
prebiotics in inﬂuencing the lipid metabolism, affecting the
central regulatory mechanisms to control fatty acid oxidation
(i.e. PPARα) and affect fat absorption and turnover directly in
the gut (i.e. ANGP4). The decreased TAG concentrations in
animals fed KJ associated with increased transcripts of PPARα
(Table 1 and Fig. 2) are in good accordance with the proven
effect of FOS in reducing hepatic TAG accumulation through a
PPARα stimulation of fatty acid oxidation(8). Overall, detailed
information on metabolism in mitochondria, a vital organelle
for fatty acid oxidation, is especially lacking and would be
important to further evaluate the inﬂuence of prebiotics on the
regulation of liver-related diseases. The administration of KJ
caused a signiﬁcant increase in ANGP4 mRNA expression in
comparison with those values determined in ARa-fed animals
(Fig. 2), thus suggesting that it mainly affected fatty acid meta-
bolism, preventing macrophage activation in mesenteric lymph
nodes(29). This could help to explain the decreased proportion
of macrophages in the liver in animals fed ARa/KJ (Fig. 4). The
observation that ARa/KJ-fed animals showed decreased TAG
concentrations (Table 1) allows hypothesising a post-
transcriptional control of ANGP4. This is in agreement with
the reported proteolytic cleavage of ANGP4 at the linker region,
releasing nANGP4 and the monomeric C-terminal portion of
ANGP4, which exert different biological functions(30). A differ-
ential PPAR (-α, -γ and -δ) mRNA expression has been seen to
be modulated by long-chain fatty acids (LCFA), which led to the
suggestion that these compounds could act as ligand but not as
regulators of these receptors(31). Thus, the decreased plasmatic
concentration of ARa in KJ-fed animals indicates the positive
inﬂuence of KJ in limiting the absorption of ARa that could
constitute an additional factor contributing to the LCFA-
mediated regulation of PPAR, as previously indicated(31). As a
consequence, a decreased production of the biologically active
n/c-ANGP4 monomers relative to the ARa group could reduce
the mobilisation of fatty acids from storage tissues as well as
macrophage activation(32). These changes are in agreement
with the decreased CD11b/c+ cell proportion inﬁltrated into the
liver of the ARa/KJ group relative to ARa-fed animals.
The previously reported ANGP4-mediated inhibition of lipo-
protein lipase activity, leading to hypertriglyceridaemia(33) and
enhanced uptake of TAG promoted by interaction of apoE with
the LDLr, is in accordance with the signiﬁcantly increased LDLr
mRNA expression levels in animals fed ARa (Fig. 2). Feeding KJ
to animals that received ARa favoured a positive effect, reducing
the plasmatic TAG and ARa concentrations (Table 1); however,
administration of KJ failed to positively decrease cholesterol
concentrations, supporting the absence of statistically signiﬁcant
changes in LDLr mRNA expression (Fig. 2). The increased
accumulation of TAG and their subsequent oxidation could
favour inﬂammatory response(s) through interaction with
TLR4 (34), supported by an increased TLR4 mRNA expression
level in animals fed ARa. In this scenario, the administration of KJ
failed to decrease the hepatic TLR4 expression levels of ARa/KJ-
fed animals (Fig. 2). Metabolic effects derived from the produc-
tion of SCFA from prebiotic consumption could also be expected
in relation to lipogenesis and energy homoeostasis(34). For
example, there has been reported a protective role for these
SCFA against diet-induced obesity due to their regulatory effects
on the production of gut hormones such as glucagon-like
peptide-1 (GLP-1) and peptide tyrosine tyrosine (PYY) through
their interaction with the free fatty acid receptor 2 (FFAR2; also
known as GPR43)(35,36). Animals fed KJ showed concentrations
of both propionate (0·18mM) and butyrate (0·13mM) that were
much lower than those favouring the secretion of GLP-1 and PYY
production. Unfortunately, the experimental design of this study
does not allow to either directly associate or negate the potential
inﬂuence of SCFA on the liver inﬂammatory biomarkers.
Changes in lipid metabolism have been further characterised
in relation to the PL proﬁle, which are building blocks in bio-
logical membranes and potent mediators in cell homoeostasis
and inﬂammation, and in macrophage and neutrophil chemo-
taxis. Recent metabolome-based studies have also associated
alterations in immunomodulatory lipid components such as PL
levels with obesity and T2D(16). These alterations are observed
in hyperglycaemic animals that showed increased plasmatic
levels of LPC and decreased LPE (Fig. 4). Time-course
monitoring studies for 3 weeks revealed different patterns for
the LPC species, showing early (after 1 week) increases for
circulating LPC (20:0) and LPC (20:4). However, decreased
levels for LPC (20:1) were reported during the ﬁrst 3 weeks of
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monitoring, whereas LPC (20:5) levels decreased during the 1st
week of treatment, but increased during the next 2 weeks(35,36).
A similar pattern with increased circulating levels of LPC (20:2)
with low saturations was detected in ARa-fed animals (Fig. 4).
Although it was not the objective of this study, it could be of
importance to bear in mind the potential regulatory inﬂuence
that KJ administration could exert on the expression levels of
LPC acyltransferase 1 (LPCAT1), contributing to normalise LPC
levels to values found in controls. Increased levels of LPCAT1,
responsible for the transformation of LPC into PC, have been
identiﬁed as a promoting factor of hepatoma progression(37),
the most severe clinical condition associated with chronic liver
inﬂammation. The decreased PIP2 concentration quantiﬁed in
ARa/KJ-fed animals helps to explain the lower proportion of
macrophages inﬁltrated into the liver lobules, suggesting a
potential interaction on the Rac2 (Ras-related C3 botulinum
toxin substrate 2) signalling pathway.
Conclusions
The inﬂuence of KJ on several relevant biomarkers affecting
ARa-mediated alterations in the liver physiology of hypergly-
caemic animals has been monitored. Feeding a prebiotic
carbohydrate such as KJ (0·5 %, w/w diet) to animals adminis-
tered ARa ameliorated these effects, mainly decreasing plasmatic
TAG and ARa concentrations to values similar to those found in
controls. Notably, KJ contributed to decreasing the macrophage
population inﬁltrated into the liver and normalised the plasmatic
PL proﬁle in hyperglycaemic rats, which could contribute to
severity and pathological progression in liver disorders. The
results stress the potential relevance that prebiotic carbohydrates
could play in ameliorating, but mainly in preventing, liver-
associated disorders and adaptive immune responses triggered
by tissue injury and failure. Whether these effects could inﬂuence
the metabolic and inﬂammatory proﬁle of adipose tissue as well
as whole-body insulin sensitivity should be addressed in future
research. Further, human trials are warranted to support
the clinical relevance and use of prebiotics as coadjutants in
nutritional intervention strategies.
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